tradingkey.logo

Vivos Therapeutics Inc

VVOS
查看詳細走勢圖
1.970USD
-0.010-0.51%
收盤 12/19, 16:00美東報價延遲15分鐘
16.29M總市值
虧損本益比TTM

Vivos Therapeutics Inc

1.970
-0.010-0.51%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.51%

5天

-4.83%

1月

-7.08%

6月

-29.64%

今年開始到現在

-54.08%

1年

-60.44%

查看詳細走勢圖

TradingKey Vivos Therapeutics Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Vivos Therapeutics Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名127/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價5.50。中期看,股價處於下降通道。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Vivos Therapeutics Inc評分

相關信息

行業排名
127 / 208
全市場排名
296 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 3 分析師
買入
評級
5.500
目標均價
+154.63%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Vivos Therapeutics Inc亮點

亮點風險
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.
業績增長期
公司處於發展階段,最新年度總收入15.03M美元
估值合理
公司最新PE估值-1.11,處於3年歷史合理位
機構減倉
最新機構持股815.76K股,環比減少2.60%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉91.46K股

Vivos Therapeutics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Vivos Therapeutics Inc簡介

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.
公司代碼VVOS
公司Vivos Therapeutics Inc
CEOHuntsman (R. Kirk)
網址https://vivos.com/

常見問題

Vivos Therapeutics Inc(VVOS)的當前股價是多少?

Vivos Therapeutics Inc(VVOS)的當前股價是 1.970。

Vivos Therapeutics Inc 的股票代碼是什麼?

Vivos Therapeutics Inc的股票代碼是VVOS。

Vivos Therapeutics Inc股票的52週最高點是多少?

Vivos Therapeutics Inc股票的52週最高點是7.950。

Vivos Therapeutics Inc股票的52週最低點是多少?

Vivos Therapeutics Inc股票的52週最低點是1.925。

Vivos Therapeutics Inc的市值是多少?

Vivos Therapeutics Inc的市值是16.29M。

Vivos Therapeutics Inc的淨利潤是多少?

Vivos Therapeutics Inc的淨利潤為-11.14M。

現在Vivos Therapeutics Inc(VVOS)的股票是買入、持有還是賣出?

根據分析師評級,Vivos Therapeutics Inc(VVOS)的總體評級為買入,目標價格為5.500。

Vivos Therapeutics Inc(VVOS)股票的每股收益(EPS TTM)是多少

Vivos Therapeutics Inc(VVOS)股票的每股收益(EPS TTM)是-1.772。
KeyAI